Wednesday, October 6, 2010

Intraarterial nicardipine and milrinone vasospasm in subarachnoid hemorrhage


BACKGROUND: Vasospasm is a potentially devastating complication after aneurysmal subarachnoid hemorrhage. Although endovascular treatment with intraarterial nicardipine and milrinone is an accepted clinical treatment strategy, there is little information either on hemodynamic management during treatment or on outcome and consequences of the hemodynamic management. We tested 2 hypotheses: (1) intraarterial administration of nicardipine and milrinone to treat cerebral vasospasm would require increased administration of vasoconstrictor to support arterial blood pressure at target levels; and (2) high-dose vasopressors administered to increase blood pressure in these patients would lead to systemic acidosis and end-organ ischemic damage.


METHODS: We conducted a single-center, retrospective review of consecutive patients with clinically symptomatic vasospasm after aneurysmal subarachnoid hemorrhage that failed medical management with “triple H therapy” and subsequently received intraarterial nicardipine and/or milrinone between March 2005 and July 2007.


RESULTS: Of 160 endovascular interventions in 73 patients (aged 52 ± 10 years; 50 women), 96 received only nicardipine, 5 only milrinone, and 59 both drugs. General anesthesia with muscle relaxation was performed for 93% of procedures.


  • During treatment, both the number and dose of vasopressors required to maintain arterial blood pressure at target levels increased; the median dose of phenylephrine increased from 200 (n = 121) to 325 μg/min (n = 122), norepinephrine increased from 12 (n = 60) to 24.5 μg/min (n = 87), and vasopressin infusions increased from 7 to 24. Nonetheless, arterial blood pressure decreased 13% during treatment.
  • In more than 90% of procedures, the postprocedure angiogram showed improved vessel caliber.
  • A single patient demonstrated troponin T increase;
  • no patients had a decrease in renal function, bowel or peripheral ischemia, systemic acidosis, or acute stroke.
  • Overall mortality was 11%.

CONCLUSIONS: Intraarterial administration of nicardipine and/or milrinone requires use of vasopressors to maintain arterial blood pressure. Despite high doses of vasoconstrictors, treatment has low mortality, minimal end-organ ischemic damage or systemic acidosis, and results in improved caliber of cerebral vessels affected by vasospasm.



Hemodynamic Management and Outcome of Patients Treated for Cerebral Vasospasm with Intraarterial Nicardipine and/or Milrinone - Anesthesia & Analgesia, March 2010 vol. 110 no. 3 895-902

Tuesday, October 5, 2010

Q: Esmolol is metabolised in...?


A; RBC

Esmolol is called esmolol because it has side chain called Ester-methyl which allows for quick hydrolysis. Esmolol is rapidly hydrolyzed by esterases in the cytosol of red blood cells. Its metabolism is not affected by hepatic or renal failures

Monday, October 4, 2010

Pneumthoraces in HIV/PCP patients


Q: 38 year old male with AIDS presented to ICU with respiratory failure. Patient few hours after intubation developed pneumothorax. Chest tube is inserted but there was no resolution of pneumothorax. Senior resident inserted second chest tube without any relief. Hypoxia persisted?


A; The development of pneumothorax in the setting of severe PCP in AIDS patient, represents a difficult problem to manage, and patients may require multiple chest tubes or even surgical interventions. Mortality is very high.

Sunday, October 3, 2010

Q: Which blood test can be use to monitor the progress or improvement of TTP (Thrombotic thrombocytopenic purpura) while on plasmapharesis?


A; LDH

Lactate dehydrogenase levels are generally used to monitor TTP activity. Plasmapheresis may need to be continued till patients cease to consume platelets. Research protocols have used improvement or normalization of LDH as a measure for ending plasmapheresis.

Saturday, October 2, 2010


Q: Does Phenytoin (Dilantin) get cleared by hemodialysis or hemoperfusion?


A; No (clinically insignificant removal)

Clinical significance:

  • In Phenytoin toxicity/overdose, Hemodialysis or hemoperfusion are ineffective for enhancing elimination.
  • Hemodialysis patients do not require extra dosing post dialysis though require frequent monitoring due to lower albumin level.

Friday, October 1, 2010

IVIG for the treatment of Clostridium difficile?

Clostridium difficile is the most common infectious cause of nosocomial healthcare-associated diarrhea. The increasing prevalence of C difficile, spread in the community, virulence and frequent relapse has created an urgent need to identify new effective treatments for C. difficile infection. Among these, intravenous immunoglobulin (IVIG) is used for cases of severe C. difficile infection. We undertook a systematic review to examine the published literature pertaining to the use of immunoglobulin for C. difficile infection. Four retrospective studies and five case reports that addressed the use of IVIG for the treatment of C. difficile infection were identified. One study on the use of oral immunoglobulin was identified. Although overall there appear to be benefits to using IVIG in recurrent severe disease, the small sample sizes and lack of control groups in three of the four studies do not allow recommendations to be made regarding the use of immunoglobulin in C. difficile infection. Further research is urgently needed to clarify the role of immunoglobulin – intravenous or oral – for the treatment of C. difficile infection.


The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review - INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, Volume 13, Issue 6, Pages 663-667 (November 2009)